Faculty

Institution

Unit

Venue

Richard T. Maziarz, M.D.

Professor of Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Medicine

Department Of Molecular Microbiology And Immunology

Department Of Pediatrics

Division Of Oncological Sciences

Center For Experimental Therapeutics

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Center Of The Amyloidosis

Department of Medicine

Division Of Hematology/Medical Oncology

Division of Hematology & Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Richard T. Maziarz, M.D., is a Professor of Medicine at Oregon Health & Science University. His research focuses on hematological malignancies, allogeneic bone marrow transplantation, and cellular therapy, including tumor-infiltrating lymphocyte (TIL) therapy and CD19 CAR T-cell products. His recent work examines transplant outcomes in patients aged ≥70, post-transplant cyclophosphamide dosing, and a phase 1 trial of ruxolitinib plus venetoclax for relapsed/refractory acute myeloid leukemia.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Richard T. Maziarz, M.D.

Oregon Health & Science University

Professor of Medicine

You can click a keyword to filter the displayed items

hematology medicine cell transplantation immunology oncology clinical transplantation transplantation medicine bone marrow transplantation cellular therapy stem cell transplantation organ transplantation hematological malignancies regenerative medicine pharmacology cell therapy lymphoid neoplasia medicinal research cancer research leukemia cancer treatment clinical research clinical trials cancer care dermatology outcomes research pharmacotherapy graft survival experimental medicine liver transplantation laboratory medicine transplant infectious diseases clinical immunology hematopoietic cell transplantation transplant surgery graft rejection stem-cell therapy stem cell research myeloid neoplasia hematologic malignancies transplantation proceeding blood transfusion hla typing acute myeloid leukemia nonmyeloablative conditioning multiple myeloma cancer management tissue transplantation allogeneic transplantation cell replacement therapies therapeutic efficacy cancer biology myelodysplastic syndrome large b-cell lymphoma clinical mycology blood cells bone marrow failure molecular cancer jama oncology cancer genomics cytogenetics hemostasis molecular immunology stem cell mobilization acute myelogenous leukemia myelodysplastic syndromes adult patients clinical evidence unrelated donors granulocyte colony-stimulating factor graft-versus-host disease immunogenetics comorbidity phase iii acute graft-versus-host disease clinical gerontology personalized treatments internal medicine autoimmune diseases translational research bioethics autoimmunity pathology translational medicine public health medical sociology haematopoiesis preventive healthcare stem cells immune responses pediatric transplantation health policy individualized medicine medical history xenotransplantation cancer immunotherapy preventive medicine cancer letter immunity (medicine) immunotherapy public health ethics radiation oncology

Notable Scholarly Works

Notable Federal Grants

Collaborators

Allogeneic Transplant Outcomes in Adults Aged ≥75 Receiving Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

hematologyorgan transplantationmedicineclinical transplantationgraft survivalpost-transplant cyclophosphamideallogeneic transplant outcomesbone marrow transplantationcell transplantationcritical carestem cell transplantationhealth sciencestransplantation medicine

Allogeneic Transplant Outcomes in Patients Aged ≥70 vs 70 With Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

hematologyorgan transplantationmedicineclinical transplantationpost-transplant cyclophosphamidefludarabine/melphalan conditioningallogeneic transplant outcomesbone marrow transplantationcell transplantationcritical carestem cell transplantationtransplantation medicine

Comparative Outcomes of 80 Mg/Kg2 vs 100 Mg/Kg 2 Post-Transplant Cyclophosphamide Following Flumel100 Conditioning in Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy (2026)

hematologymedicineclinical transplantationhaematopoiesiscomparative outcomesbone marrow transplantationmg/kg 2immunologycell transplantationstem cell transplantationtransplantation medicinemg/kg2 vs 100transplantation proceedingclinical trials

Comprehensive Benchmarking of Outcomes After Anakinra Treatment for Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (Icans). Transplantation and Cellular Therapy (2026)

immune responsesmedicineautoimmune diseasescellular therapyneuroinflammationimmunotoxicologycomprehensive benchmarkingimmunotherapyimmunologyautoimmunityexperimental medicineanakinra treatmentpharmacotherapymedicinal researchtreatment development

Impact of Cd19 Car Product on Resource Utilization Through Day 28 for Large Cell Lymphoma. Transplantation and Cellular Therapy (2026)

Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (Til) Therapy Program Using Commercial Lifileucel. Transplantation and Cellular Therapy (2026)

hematologymelanoma patientscellular therapymedicinetherapy programoncologyradiation oncologyimmune checkpoint inhibitorscancer carecommercial lifileucelmelanomatumor microenvironment

Real World Outcomes of a Single-Center Tumor Infiltrating Lymphocyte (Til) Melanoma Therapy Program With Commercial Lifileucel.. Transplantation and Cellular Therapy (2026)

melanoma therapy programcancer immunotherapycellular therapymedicineoncologyradiation oncologyimmune checkpoint inhibitorsimmunotherapycancer immunosurveillancecommercial lifileuceljama oncologyreal world outcomesmelanomatumor microenvironmentpathology

Results of a Phase 1 Trial Testing Ruxolitinib Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Blood Neoplasia (2026)

hematologymedicineoncologyhematological malignanciesmetronomic chemotherapymyeloid neoplasialeukemiapharmacologyphase 1pharmacotherapyclinical trials

105 | Interim Results of Tandem Cd20‐Cd19‐Directed Non‐Cryopreserved Car‐T Cells—Zamtocabtagene Autoleucel in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Hematological Oncology (2025)

cancer immunotherapycellular therapyoncologyradiation oncologycell therapyhematological malignanciesimmunotherapylymphoid neoplasiaimmunologycell transplantation

Activity of Autologous Anti-Cd19 Chimeric Antigen Receptor T-Cell Therapy in Cd19-Negative Large B-Cell Lymphoma: A Cell Therapy Consortium Real World Experience. Blood (2025)

cancer immunotherapycellular therapycell therapyleukemiaimmunotherapylymphoid neoplasiaimmunologycell transplantationpathology

1
2
3
4
5
58
10 / page

Richard T. Maziarz, M.D.

Professor of Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Medicine

Department Of Molecular Microbiology And Immunology

Department Of Pediatrics

Division Of Oncological Sciences

Center For Experimental Therapeutics

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Center Of The Amyloidosis

Department of Medicine

Division Of Hematology/Medical Oncology

Division of Hematology & Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Richard T. Maziarz, M.D.

Oregon Health & Science University

Professor of Medicine

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Allogeneic Transplant Outcomes in Adults Aged ≥75 Receiving Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

Allogeneic Transplant Outcomes in Patients Aged ≥70 vs 70 With Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

Comprehensive Benchmarking of Outcomes After Anakinra Treatment for Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (Icans). Transplantation and Cellular Therapy (2026)

Impact of Cd19 Car Product on Resource Utilization Through Day 28 for Large Cell Lymphoma. Transplantation and Cellular Therapy (2026)

hematologymelanoma patientscellular therapymedicinetherapy programoncologyradiation oncologyimmune checkpoint inhibitorscancer carecommercial lifileucelmelanomatumor microenvironment

Real World Outcomes of a Single-Center Tumor Infiltrating Lymphocyte (Til) Melanoma Therapy Program With Commercial Lifileucel.. Transplantation and Cellular Therapy (2026)

Results of a Phase 1 Trial Testing Ruxolitinib Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Blood Neoplasia (2026)

hematologymedicineoncologyhematological malignanciesmetronomic chemotherapymyeloid neoplasialeukemiapharmacologyphase 1pharmacotherapyclinical trials

cancer immunotherapycellular therapyoncologyradiation oncologycell therapyhematological malignanciesimmunotherapylymphoid neoplasiaimmunologycell transplantation

Activity of Autologous Anti-Cd19 Chimeric Antigen Receptor T-Cell Therapy in Cd19-Negative Large B-Cell Lymphoma: A Cell Therapy Consortium Real World Experience. Blood (2025)

cancer immunotherapycellular therapycell therapyleukemiaimmunotherapylymphoid neoplasiaimmunologycell transplantationpathology

1
2
3
4
5
58
10 / page